Every letter we have printed

You write that only one laboratory attached its chromatogram to the private buyer report. That was probably us. We started doing it five years ago because the PDF seemed incomplete without it. It costs us nothing to add — the instrument generates it automatically — and it solves exactly the dispute-resolution problem you describe. More laboratories should do it, and the reason they do not is not technical.

On the section about diode-array detection and peak purity, I would add that true peak purity assessment requires library matching or at least spectral comparison across the peak width. A homogeneous spectrum tells you the peak is probably pure. A spectrum that shifts across the peak tells you it is not, and that information closes a gap the article identifies correctly.

The table showing what each method can detect is valuable but incomplete. You show no row for C-terminal truncation or N-terminal truncation as distinct phenomena. These are not rare, and they often elute differently depending on which end is missing. A generic gradient might resolve them; an improperly designed orthogonal method might not. The capability matrix should separate these cases.

Your article argues for two orthogonal methods and reports the lower figure, but the people running a single twelve-minute method have a cost story you do not address. A full orthogonal pair doubles the turnaround and at least doubles the cost, which is why the market does not do it. The criticism of method disclosure is fair. The criticism that a single method is wrong is unfair to the constraints people operate under.

Sub-two-micron columns changed everything about what is practical for peptide separations, but I would push back on the statement that particle size gains are costless. The pressure limit of most commercial instruments is three hundred bar, and trying to force 1.7-micron particles at eight millilitres per minute on a 4.6-millimetre column will send you there quickly. Peak capacity is not free.

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

Parcel 7 reached thirty-eight degrees for nearly four hours and you then tell readers not to worry unduly. I accept the solid-state argument. I would still like to know what the material looked like on analysis, and your article does not say.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

Nothing in this file addresses what to do when you realise mid-week that you have made an error. I gave double my dose on a Sunday and could find no guidance anywhere about what that meant.

I want to object to the framing of dose reduction as measurement. In practice it is experienced as failure, and telling people it is a thermostat does not change how the appointment feels. The language problem is real and you have solved it rhetorically rather than actually.

Thank you for saying plainly that the maximum dose is not the goal. I stopped at 10 mg fourteen months ago because it was working and I was tired of arguing about it. Every article I read before yours implied I had given up early.

Your piece treats the four-week step as arithmetic, and I accept the arithmetic, but my prescriber moved me up every two weeks and I reached the top dose without difficulty. I do not think the schedule is as constraining as you suggest.

You keep insisting on peptide content rather than purity when discussing dose certainty. I have looked at a dozen certificates from four different testing services and content is reported on perhaps a third of them. What are readers supposed to do with an absence?

The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.

You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.

You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

You say no dose-equivalence data exists between agents in this class. During the shortage my pharmacy substituted one for another on the basis of a conversion table they had printed from somewhere. Where would such a table have come from?

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

Parcel 7 reached thirty-eight degrees for nearly four hours and you then tell readers not to worry unduly. I accept the solid-state argument. I would still like to know what the material looked like on analysis, and your article does not say.

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.

The statistics section is the part of this I will be sending to people. I had assumed a passed sterility test meant something about the batch. It had not occurred to me that a batch with one contaminated vial in a hundred passes four times out of five.

You keep saying you are criticising documentation and not honesty. I think that distinction is doing more work than it can bear. If a company knows buyers read a purity certificate as a safety document and issues one anyway, the omission is doing something.

I photograph every cake now because of an earlier piece of yours, and last month it paid for itself. Two vials from the same box, one a proper matte plug and one a collapsed glassy disc. The supplier replaced both without argument when I sent the photographs.